Abstract
Background The swift development of vaccines targeting SARS-CoV-2, which have been shown to generate significant immune responses and offer considerable protection against disease, has been met with worldwide commendation. However, in the context of an ongoing pandemic there is an interplay between infection and vaccination. While infection can grow exponentially, potentially overwhelming healthcare resources, vaccination rates are generally limited by both supply and logistics. With the first SARS-CoV-2 vaccines receiving medical approval requiring two doses, there has been scrutiny on the spacing between doses; an elongated period between doses would allow more of the population to receive a first vaccine dose in the short-term generating wide-spread partial immunity.
Methods Focusing on data from England, we investigated prioritisation of a one dose or two dose vaccination schedule given a fixed number of vaccine doses and with respect to a measure of maximising averted deaths. We optimised outcomes for two different estimates of population size and relative risk of mortality for at-risk groups within the Phase 1 vaccine priority order in England, for different amounts of available vaccine and for different vaccine efficacies.
Findings We find that vaccines offering relatively high protection from the first dose (compared to the efficacy derived from two doses) favour strategies that prioritise giving more people one dose rather than a smaller number two. The optimal mix of one and two doses between the defined priority groups of Phase 1 shows a pattern of returning to give second doses to the highest risk groups as the number of available doses increases.
Discussion While this work highlights that an optimal timing of first and second doses between the Phase 1 priority groups can substantially reduce the overall mortality risk to the population, there also needs to be careful consideration of the precise timing between first and second doses as well as the logistics of vaccine delivery.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This report is independent research funded by the National Institute for Health Research (NIHR) [Policy Research Programme, Mathematical \& Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response; NIHR200411]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. It has also been supported by the Medical Research Council through the COVID-19 Rapid Response Rolling Call [grant number MR/V009761/1] and through the JUNIPER modelling consortium [grant number MR/V038613/1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used to conduct this study are provided in the main manuscript. Code is available at https://github.com/EdMHill/fixed_num_vaccine_doses_one_vs_two_dose_prioritisation.
